Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus

INTRODUCTION/AIM: Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of long-acting and short-acting insulin analogs. The primary objective of this study was to investigate the pharmacodynamic response of once-daily IDegAsp dosing in patients with type 1 diabetes. Pharmacokinetic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Heise, Tim, Nosek, Leszek, Roepstorff, Carsten, Chenji, Suresh, Klein, Oliver, Haahr, Hanne
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2014
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4065302/
https://ncbi.nlm.nih.gov/pubmed/24888255
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-014-0070-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars